BG Medicine's CardioSCORE test has received CE Mark, which enables the commercial sale of it in the EU and other countries that recognize the CE Mark.
The CardioSCORE test is a patented diagnostic blood test designed to improve risk prediction of major cardiovascular events beyond traditional risk factor assessments, such as the Framingham Risk Score and European SCORE.
The test is performed on a standard blood sample and uses algorithmic analysis to fuse the results of seven reimbursed protein assays.
BG Medicine president and chief executive officer Eric Bouvier said the company is happy to bring the benefits of the CardioSCORE test to patients and physicians in Europe.
"Obtaining the CE Mark for the CardioSCORE test is not only a significant milestone in the prevention and treatment of cardiovascular disease but also a critical advancement in our company's continued transformation into a full-scale commercial organization," Bouvier added.
